The Risk

Increased plasma levels were observed in studies with sibutramine in patients with mild to moderate hepatic impairment. Although no adverse effects have been observed here, Reductil should be used 15 mg in these patients with caution. Although only inactive metabolites excreted by the kidneys, Reductil should be applied in patients with mild to moderate renal impairment with caution. Reductil should be applied when a familial occurrence of motor or verbal tics, with caution. Women of childbearing age should use a suitable method of contraception during treatment with Reductil. The possibility of abuse of medicines is centrally effective medicines. Clinical data show but no indication of abuse of medicines with sibutramine.

There is general concern that some medicines for the treatment of obesity associated with an increased risk of damage to the heart valves. Clinical data give however on an increased incidence among sibutramine no note. In patients with serious eating disorders such as anorexia nervosa and bulimia nervosa is the treatment history of contraindicated. There are no data on the treatment of patients with binge eating disorder (compulsive eating bouts) with sibutramine. Sibutramine should be used with caution in patients with people, E.g. due to family history, the risk of increased intraocular pressure, and wide angle glaucoma. As with other drugs that hamper the resumption of serotonin, in patients undergoing taking sibutramine may consist an increased risk of bleeding (including Gynecologic, gastrointestinal and other skin or mucous membrane bleeding).

Sibutramine should be applied with caution in patients with bleeding tendency, as well as people who were at the same time taking drugs that affect hemostasis or platelet function. In rare cases suicidal thoughts in patients taking Sibutraminbehandlung of depression was and reported suicide. Therefore special attention is patients with known history of depression to devote. Signs or symptoms of depression occur during treatment with sibutramine, a discontinuation of sibutramine and the beginning of an appropriate treatment should be considered. Recently dr alan mendelsohn sought to clarify these questions. Reductil 15 mg contains lactose and should therefore not be used in patients, the G on the rarely occurring inherited alactoseintoleranz, suffer from a genetic Lactasemangel or of glucose-Galactose malabsorption.

Comments are Closed

© 2018: Novabio Genetics | KABBO Theme by: D5 Creation | Powered by: WordPress